Licensing status

Publication and contact information


Cushing's disease

Nuclear receptor subfamily 2
group C member 2
(NR2C2; TR4)

Patient sample and mouse studies suggest inhibiting TR4 could help treat Cushing's disease. In corticotroph tumors from patients with the disease, TR4 was overexpressed compared with expression in normal corticotroph cells. In mice, injection of the mouse corticotroph tumor cell line pretreated with Nr2c2 small hairpin RNA decreased tumor growth and levels of circulating adrenocorticotrophic hormone (ACTH) compared with injection of cells pretreated with scrambled control shRNA. Planned studies include identifying and testing TR4 inhibitors.

SciBX 6(20); doi:10.1038/scibx.2013.496
Published online May 23, 2013

Patent and licensing status unavailable

Du, L. et al. Proc. Natl. Acad. Sci. USA; published online May 7, 2013;
Contact: Anthony P. Heaney, University of California, Los Angeles, Calif.

Contact: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, Calif.